Publication | Closed Access
A Major Inhibitor of Phenytoin Binding to Serum Protein in Uremia
44
Citations
0
References
1988
Year
Major InhibitorSerum ProteinPharmaceutical ScienceHealthy SubjectsPharmacotherapyTranslational PharmacologyUremic SerumMedicinal ChemistryRenal FunctionPhenytoin BindingClinical ChemistryChronic Kidney DiseaseBiochemistryKidney FailurePharmacologyUrologyNatural SciencesDiabetic Kidney DiseaseClinical PharmacologyHuman Serum AlbuminMedicineNephrologyKidney ResearchDrug Discovery
A major endogenous ligand substance, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), accumulated in the sera of uremic patients, inhibited phenytoin binding to pooled serum obtained from healthy subjects and to human serum albumin in a concentration usually observed in the sera of patients with uremia. This suggests that CMPF is a major drug-binding inhibitor present in uremic serum and may be one of the so-called 'uremic toxins'.